HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Zolpidem

HCID 5732
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
82626-48-0
Standard SMILES
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1
InChIKey
ZAFYATHCZYHLPB-UHFFFAOYSA-N
Molecular formula
C19H21N3O
Average molar mass
307.4 g/mol
Monoisotopic mass
307.1684623

Overview

Zolpidem is an imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position. It has a role as a central nervous system depressant, a sedative and a GABA agonist.

Names & identifiers

Preferred name
Zolpidem
IUPAC
N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
English name
Zolpidem
Molecular formula
C19H21N3O
Molecular weight
307.39

Names & synonyms

zolpidem82626-48-0ZolpidemumSanvalZolpidem civN,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamideEdlularDTXSID7045946Zolpi LichN,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide7K383OQI23Imidazo(1,2-a)pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-
Show more names
IvadalNiotalEdluarCS-1159ZoipidemSL-80.0750SL-80.0750-23NZolpidem (CRM)Stilnoct:Stilnox
DTXCID5025946CHEBI:10125N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamideSL 800750 23 NImidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-N,N-dimethyl-2-(6-methyl-2-(4-methylphenyl)imidazo(1,2-a)pyridin-3-yl)acetamideRefChem:6366SL-800750-23-N

Database identifiers

CAS
82626-48-0
PubChem CID
5732

Properties

Computed structural properties

XLogP
2.5
Topological polar surface area
37.6 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
2
Rotatable bonds
3
Heavy atoms
23
Formal charge
0
Complexity
417

Experimental & physicochemical properties

Drugs · 6 items

DEA NFLIS-Drug Category -> Depressants and Tranquilizers

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Hypnotic

Pharmaceuticals -> Used in Switzerland

LogP2.42
Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives

Pharmaceuticals

Melting Point · 2 items

193-197

196 °C

Physical DescriptionSolid
Dissociation ConstantsStrongest basic, 5.65
Collision Cross Section · 2 items

177.6 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated]

177.2 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 10% (1 of 10) of reports.

Warning

H302 (90%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P273, P301+P317, P304+P340, P319, P330, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 10 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

DEA schedule IV controlled substance

REACH registered substance: N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide (EC: 617-367-3)

Hazard Classes and CategoriesAcute Tox. 4 (90%)

Toxicology

Treatment · 1 item

General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. sedative hypnotic effect was shown to be reduced by flumazenil and therefore may be useful; however, flumazenil administration may contribute to the appearance of neurological symptoms (convulsions). As in all cases of drug overdose, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Hypotension and CNS depression should be monitored and treated by appropriate medical intervention. Sedating drugs should be withheld following zolpidem overdosage, even if excitation occurs. The value of dialysis in the treatment of overdosage has not been determined, although hemodialysis studies in patients with renal failure receiving therapeutic doses have demonstrated that zolpidem is not dialyzable. (L1712)

Chemistry & industry

Pharmacology

ATC Code · 3 items

N05CF02

N - Nervous system

QN - Nervous system

Protein Binding92.5 ± 0.1%
Pharmacodynamics · 1 item

**Effects on the central nervous system (CNS)** This drug has CNS depressant effects, which may include somnolence, decreased alertness, sedation, drowsiness, dizziness, and other changes in psychomotor function. Due to the above effects, the FDA has recommended an initial dose of zolpidem (immediate-acting) is a single dose of 5 mg for women and a single dose of 5 or 10 mg for men, immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening. Refer to product labeling for detailed information,. **Effects on memory** Controlled studies in adults using objective measures of memory demonstrated no significant evidence of next-day memory impairment after the administration of zolpidem. On the contrary, in a clinical study involving the administration of zolpidem doses of 10 and 20 mg, a marked reduction in a next-morning recall of information relayed to subjects during peak drug effect (90 minutes after dosing) was observed. These subjects experienced a condition known as _anterograde amnesia_. Subjective evidence from adverse event data has suggested that anterograde amnesia may occur after zolpidem administration, mainly at doses above 10 mg. **Effects on psychomotor function** This drug may cause decreased psychomotor performance. Additive psychomotor effects may occur with other drugs that cause depression of psychomotor function, including alcohol. Patients taking zolpidem should be cautioned against participating in hazardous activities or occupations requiring complete mental alertness or motor coordination, including operating machinery or driving a motor vehicle after ingesting the drug. Potential impairment of the performance of the above types of activities may also occur the day after zolpidem ingestion, especially at higher doses and ingestion of the extended-release form,. **Effects on insomnia and sleep stages** Evidence suggests that this drug is associated with minimal rebound insomnia. During clinical trials with patients using zolpidem on an ‘as-needed’ basis, zolpidem use resulted in global improvements in sleep. Zolpidem has been demonstrated to decrease sleep latency (the time it takes to fall asleep) for up to 35 days in controlled clinical studies. In studies measuring the percentage of sleep time spent in each sleep stage, zolpidem has primarily been shown to preserve sleep stages. Sleep time spent in stages 3 and 4 (deep sleep) was measured as similar to placebo with only minor and inconsistent changes in REM (paradoxical) sleep at the recommended dose. **Next-day residual effects** In 2013, the FDA issued a statement warning that patients who take zolpidem extended-release (Ambien CR)―either 6.25 mg or 12.5 mg―should not drive or participate in other activities requiring full mental alertness the day after taking the drug, due to the fact that zolpidem concentrations can remain increased the next day, and impair the ability to perform these activities,. Patients may decrease their risk of next-morning impairment by taking the lowest dose of their insomnia medicine that treats their symptoms, according to the FDA. Specific dosing recommendations for both men and women are included in this statement. This information is also available on product labeling,. **Rebound effects** There was no polysomnographic (objective) evidence of rebound insomnia at normal doses, in studies evaluating sleep on the nights following discontinuation of zolpidem tartrate. Subjective evidence of impaired sleep in the elderly on the first post-treatment night was observed at doses higher than the recommended 5mg dose for elderly patients.

Related reactions

8 records
New reaction record
HRID 230245 reaction equation
HRID 230245As reactant
HRID 837915 reaction equation
HRID 837915As product
HRID 858884 reaction equation
HRID 858884As reactant
HRID 958283 reaction equation
HRID 958283As reactant
HRID 1066183 reaction equation
HRID 1066183As reactant
HRID 1066184 reaction equation
HRID 1066184As reactant
HRID 1066185 reaction equation
HRID 1066185As reactant
HRID 2239258 reaction equation
HRID 2239258As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
DTXSID
DTXSID7045946
ChEMBL
CHEMBL911
ChEBI
CHEBI:10125
UNII
7K383OQI23
EC Number
617-367-3
Nikkaji
J33.161I

Physicochemical properties

Melting point
189 · 189-191°C
Density
1.12 · 1.12±0.1 g/cm3(Predicted)
Flash point
9 ℃ · 9℃
storage temp.
Store at RT
solubility
45 % · 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.3 mg/mL
form
solid
pka
6.2 · 6.2(at 25℃)
color
white
Water Solubility
10 mg/L · <10mg/L(room temperature)
Major Application
clinical testing
InChI
1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
InChIKey
ZAFYATHCZYHLPB-UHFFFAOYSA-N
SMILES
[n]21c(nc(c2CC(=O)N(C)C)c3ccc(cc3)C)ccc(c1)C
CAS DataBase Reference
82626 · 82626-48-0(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
zolpidem
FDA UNII
7 K383OQI23 · 7K383OQI23
ATC code
5 CF02 · N05CF02
NIST Chemistry Reference
Zolpidem(82626-48-0)
Comptox DTXSID
7045946 · DTXSID7045946
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Symbol(GHS)
7 · GHS07,GHS09
Signal word
Warning
Hazard statements
302 · H302-H336-H411
Precautionary statements
261 · P261-P264-P270-P271-P273-P301+P312
target organs
Eyes,Central nervous system
Hazard Codes
Xi
Risk Statements
36 · 36/37/38
Safety Statements
26 · 26-36
RIDADR
1230 · UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany
3 · 3
RTECS
5109750 · NJ5109750
HS Code
2933990030 · 2933990030
Storage Class
3 · 3 - Flammable liquids
Hazard Classifications
3 DermalAcute · Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1
REACH Registrations
Active
Health EffectsThey cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive.
Hepatotoxicity · 1 item

In multiple premarketing randomized controlled trials, zolpidem was not associated with an increased rate of serum enzyme elevations in comparison to placebo therapy. A single instance of clinically apparent liver injury has been reported. The onset of injury was 2 days after a single dose of zolpidem and was accompanied by abdominal pain, but no jaundice. The pattern of liver enzyme elevations was hepatocellular and the abnormalities were self-limited, although they seemed to recur on reexposure. Zolpidem is metabolized in the liver by the cytochrome P450 system (predominantly CYP 3A4) and can cause drug-drug interactions, although such interactions are rare. Thus, zolpidem has not been linked to cases of liver injury with jaundice, but rarely may cause transient, mild-to-moderate serum enzyme elevations with or without symptoms.

Adverse Effects · 1 item

Adverse effects of zolpidem include anaphylaxis, changes in behavior, withdrawal, and central nervous system (CNS) depression. In rare situations, patients have reported tongue, larynx, or glottis swelling in the form of angioedema. Also, patients have reported shortness of breath, airway closure, nausea, and vomiting. If these events are reported, do not use zolpidem. Patients who experience closure in the throat, glottis, or larynx should be sent to the emergency department.

Exposure RoutesOral. Zolpidem is rapidly absorbed from the GI tract.
Toxicity Summary · 2 items

Drug overdose with zolpidem involves CNS depression, cognitive impairments leading to drowsiness or coma, cardiovascular and respiratory depression, and other fatalities. The acute toxicity of zolpidem is less in severity than other short-acting benzodiazepines like triazolam and midazolam. However, in combined intoxication with other CNS depressant drugs, zolpidem can induce coma in patients even with a low concentration. Single-drug poisoning is benign and should not require therapeutic intervention.

Zolpidem modulates the alpha-subunit, known as the benzodiazepine receptor, within the GABA<sub>A</sub> receptor chloride channel macromolecular complex. Unlike the benzodiazepines, which non-selectively interact with all three alpha-receptor subtypes, Zolpidem preferentially binds to the alpha-1 receptor.

Signs and SymptomsSymptoms of overdose include impairment of consciousness ranging from somnolence to light coma.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

zolpidem

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation · 2 items

◉ Summary of Use during Lactation

◈ What is zolpidem?

Toxicity DataLD50: 695 mg/kg (Oral, Rat) (A308)
EPA Human Health Benchmarks for Pharmaceuticals · 6 items

Zolpidem

0.1

0.5

Use the lowest effective dose for the patient. The recommended initial dose is 5 mg for women and either 5 or 10 mg for men, taken only once per night immediately before bedtime with at least 7 to 8 hours remaining before the planned time of awakening. If the 5 mg dose is not effective, the dose can be increased to 10 mg.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 5 mg/day, Lowest Therapeutic Dose (LTD): 0.1 mg/kg-day, and Screening Dose: 0.00002 mg/kg-day.

10-Sep-19

Safety data

wgk
3
rtecs
NJ5109750
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
hs_code
2933990030
risk_code
36/37/38
Signal word
Warning
Symbol(GHS)
GHS07,GHS09
hazard_code
Xi
safety_code
26-36
Storage Class
3 - Flammable liquids
target organs
Eyes,Central nervous system
Hazard statements
H302-H336-H411
REACH Registrations
Active
Hazard Classifications
Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1
Precautionary statements
P261-P264-P270-P271-P273-P301+P312
Mechanism of Action · 1 item

Zolpidem, the active moiety of zolpidem tartrate, is a hypnotic substance with a chemical structure that is not related to the structure benzodiazepines, barbiturates, pyrrolopyrazines, pyrazolopyrimidines or other drugs exerting hypnotic effects. It interacts with a _GABA-BZ_ receptor complex and shares various pharmacological properties with the _benzodiazepine_ class of drugs. Subunit binding of the _GABAA_ receptor chloride channel macromolecular complex is thought to lead to the sedative, anticonvulsant, anxiolytic, and myorelaxant drug effects of zolpidem. The main regulatory site of the GABAA receptor complex can be found on its _alpha (α) subunit_ and is called the _benzodiazepine_ (BZ) or _omega (ω)_ receptor. At least three different subtypes of the (ω) receptor have been identified to this date. In contrast to benzodiazepine drugs, which are found to modulate all benzodiazepine receptor subtypes in a non-selective fashion, zolpidem binds the (BZ1) receptor specifically with a potent affinity for the alpha 1/alpha 5 subunits (in vitro). More recent studies suggest that zolpidem binds primarily to the alpha 1, 2, and 3 subunits of the GABA receptor,,, and not the alpha 5 subunit. The (_BZ1_) receptor is found primarily on the Lamina IV of the brain sensorimotor cortical regions, substantia nigra (pars reticulata), cerebellum molecular layer, olfactory bulb, ventral thalamic complex, pons, inferior colliculus, and globus pallidus. Specific and selective binding of zolpidem on the (BZ1) receptor is not considered absolute, however, this binding could potentially explain the relative lack of myorelaxant and anticonvulsant activity in animal studies in addition to the preservation of deep sleep (stages 3 and 4) in human studies of zolpidem at hypnotic doses.

Biological Half-LifeThe average zolpidem elimination half-life was 2.6 and 2.5 hours, for the 5 and 10 mg tablets, respectively.
Metabolism/Metabolites · 3 items

Zolpidem is metabolized to three pharmacologically by various hepatic cytochrome P450 (CYP) isoenzymes, mainly CYP3A4, but also CYP1A2 and CYP2C9,. Although zolpidem is heavily metabolized, all three metabolites are inactive. The major metabolic routes in humans are oxidation of the methyl group on the phenyl ring or the methyl group on the imidazopyridine moiety, to produce carboxylic acids (metabolites I and II), and hydroxylation of one of the imidazopyridine groups (to produce metabolite X). Another less common pathway is by the oxidation of the methyl groups on the substituted amide.

Zolpidem has known human metabolites that include methoxyzolpidem.

Zolpidem is converted to inactive metabolites in the liver. Route of Elimination: Zolpidem tartrate tablets are converted to inactive metabolites that are eliminated primarily by renal excretion. Half Life: 2.6 hours

FDA Pharmacological Classification · 6 items

7K383OQI23

ZOLPIDEM

Established Pharmacologic Class [EPC] - gamma-Aminobutyric Acid A Receptor Positive Modulator

Mechanisms of Action [MoA] - GABA A Receptor Positive Modulators

Physiologic Effects [PE] - Central Nervous System Depression

Zolpidem is a gamma-Aminobutyric Acid A Receptor Positive Modulator. The mechanism of action of zolpidem is as a GABA A Receptor Positive Modulator. The physiologic effect of zolpidem is by means of Central Nervous System Depression.

MeSH Pharmacological Classification · 2 items

Drugs used to induce SLEEP, prevent SLEEPLESSNESS, or treat SLEEP INITIATION AND MAINTENANCE DISORDERS.

Endogenous compounds and drugs that bind to and activate GABA-A RECEPTORS.

Absorption, Distribution and Excretion · 4 items

Zolpidem is rapidly absorbed from the gastrointestinal tract. In a single-dose crossover study in 45 healthy subjects given 5 and 10 mg zolpidem tartrate tablets, the average peak zolpidem concentrations (Cmax) were 59 and 121 ng/mL, respectively, occurring at a mean time (Tmax) of 1.6 hours for both doses.

Zolpidem tartrate tablets are converted to inactive metabolites that are eliminated mainly by renal excretion.

0.54 to 0.68 L/kg (in humans). In patients with long term renal insufficiency who were not yet on hemodialysis, the volume of distribution was found to increase significantly, AUC increased by 60%, and half-life nearly doubled.

In a clinical trial, after a 20mg dose, total clearance of zolpidem 0.24 to 0.27 ml/min/kg.

Tissue LocationsLiver
Cellular LocationsMembrane

Uses & manufacturing

Uses · 2 items

Use (kg; approx.) in Germany (2009): >750

For the short-term treatment of insomnia.

Use ClassificationPharmaceuticals
Applications · 6 items

DescriptionZolpidem (Item No. 15792) is an analytical reference material that is functionally categorized as a sedative. It is a non-benzodiazepine drug that is used in the treatment of insomnia, and it has been recreationally abused. This product is intended for research and forensic applications.

DescriptionZolpidem (Item No. 20648) is a certified reference material that is functionally categorized as a sedative. It is a non-benzodiazepine drug that is used in the treatment of insomnia, and it has been recreationally abused. This product is intended for research and forensic applications.

DescriptionZolpidem hemitamwe is a non-benzodiazepine hypnotic with specific agonist activity at type 1 benzodiazepine receptors, and is indicated for use in insomnia and other sleep disorders. Structurally zolpidem belongs to a chemically distinct class, thus lacking the side-effects and abuse potential of classical benzodiazepines. It is currently being studied as a pre-operative sedative.

UsesA selective benzodiazepine receptor agonist not related chemically to benzodiazepines

UsesA selective non-benzodiazepine GABAA receptor agonist. Sedative, hypnotic. Controlled substance (depresssant).

General DescriptionZolpidem (Ambien, an imidazopyridine) andeszopiclone (Lunesta, a cyclopyrrolone) are nonbenzodiazepinesand have been introduced as short- and moderate-acting hypnotics, respectively. Zolpidem exhibits ahigh selectivity for the α1 subunit of benzodiazepinebindingsite on GABAA receptor complex, whereas eszopicloneis a “superagonist” at BzRs with the subunitcomposition α1β2γ2 and α1β2γ3. Zolpidem has a rapidonset of action of 1.6 hours and good bioavailability(72%), mainly because it is lipophilic and has no ionizablegroups at physiological pH. Food can prolong the time topeak concentration without affecting the half-life probablyfor the same reason. It has short elimination half-life, becauseits aryl methyl groups is extensively α-hydroxylatedto inactive metabolites by CYP3A4 followed by furtheroxidation by aldehyde dehydrogenase to the ionic carboxylicacid. The metabolites are inactive, short-lived, andeliminated in the urine. Its half-life in the elderly or the patientswith liver disease is increased. Therefore, dosingshould be modified in patients with hepatic insufficiencyand the elderly. Because it has longer elimination half-lifethan zaleplon, it may be preferred for sleep maintenance.It was the most commonly prescribed drug for insomniain 2001.

Upstream & downstream products

Upstream raw materials

MethylamineOxalyl chlorideAcetamide, 2-diazo-N,N-dimethyl-6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine2-Bromo-N,N-dimethylacetamide2-PropynaMide, N,N-diMethyl-6-Methyl-2-(4-methylphenyl)imidazol[1,2-a]-pyridine-3-acetic acidBenzenebutanamide, β-bromo-N,N,4-trimethyl-γ-oxo-DimethylamineDimethylamine hydrochloride2-Amino-5-methylpyridine

Downstream products

6-Methyl-N,N-dimethyl-2-(4-methylphenyl)-2-hydroxyimidazo[1,2-alpha]pyridine-3-acetamide

Additional notes

DefinitionChEBI: An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.